Fortress Biotech Q2 Revenue Up 14% to $18.7M; Cash Position Strengthens to $196.6M
FBIO sits 56% above its 52-week low of $1.9 on elevated volume (2.3× avg).
Summary
Q2 2026 revenue reached $18.7 million, up 14% year-over-year, with a strengthened cash position of $196.6 million. The company also highlighted positive clinical and commercial updates from its partnered programs.
Key Events · Earnings and Guidance · FBIO
-
Q2 Revenue Up 14%
Total net revenue increased 14% to $18.7 million for Q2 2026, compared to $16.4 million in Q2 2025, driven by marketed dermatology products.
-
Cash Position Strengthens
Consolidated cash and cash equivalents totaled $196.6 million as of June 30, 2026, up $117.2 million from December 31, 2025, primarily due to the $205 million Priority Review Voucher sale.
-
Net Loss Narrows
Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, compared to net income of $13.4 million in Q2 2025, which included a one-time gain from deconsolidation.
-
Crystalys $130M Series B
Crystalys Therapeutics announced a $130 million Series B financing to support late-stage development of dotinurad, in which Fortress subsidiary Urica holds an equity position and is entitled to a 3% royalty on future net sales.
Analysis · FBIO · Life Sciences
Second quarter 2026 results showed total net revenue climbing 14% year-over-year to $18.7 million, propelled by growth in marketed dermatology products. The cash position strengthened markedly to $196.6 million, a $117.2 million increase from year-end 2025, largely reflecting the $205 million Priority Review Voucher sale in Q1. Net loss attributable to common stockholders narrowed to $(2.5) million, or $(0.08) per share, versus net income of $13.4 million in the prior-year quarter, which had included a one-time gain from deconsolidation. The filing also highlights positive clinical updates from partnered programs, including AstraZeneca's anselamimab subgroup analysis and Crystalys' $130 million Series B financing for dotinurad.
At the time of this filing, FBIO was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99M. The 52-week trading range was $1.90 to $4.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.